Emilio Esteban

16.1k total citations · 1 hit paper
161 papers, 4.1k citations indexed

About

Emilio Esteban is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Emilio Esteban has authored 161 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Pulmonary and Respiratory Medicine, 93 papers in Oncology and 39 papers in Molecular Biology. Recurrent topics in Emilio Esteban's work include Renal cell carcinoma treatment (44 papers), Lung Cancer Treatments and Mutations (40 papers) and Cancer Immunotherapy and Biomarkers (30 papers). Emilio Esteban is often cited by papers focused on Renal cell carcinoma treatment (44 papers), Lung Cancer Treatments and Mutations (40 papers) and Cancer Immunotherapy and Biomarkers (30 papers). Emilio Esteban collaborates with scholars based in Spain, United States and Italy. Emilio Esteban's co-authors include Saulius Cicėnas, Tudor–Eliade Ciuleanu, Barbara Klughammer, Lilia Stelmakh, Erzsébet Juhász, I. Melezínek, Wolfram Brugger, Aleksandra Szczęsna, Olivier Molinier and Gaëlle Klingelschmitt and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Emilio Esteban

154 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

2010 917 citations Emilio Esteban et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emilio Esteban Spain	27	2.6k	2.3k	1.2k	737	478	161	4.1k
Á. Artal Spain	20	2.5k 0.9×	3.2k 1.4×	878 0.7×	606 0.8×	320 0.7×	82	4.3k
William J. John United States	29	2.9k 1.1×	3.0k 1.3×	972 0.8×	585 0.8×	425 0.9×	84	4.5k
Charu Aggarwal United States	35	1.9k 0.7×	2.6k 1.1×	889 0.7×	801 1.1×	341 0.7×	202	4.1k
Takeshi Hanagiri Japan	35	1.8k 0.7×	1.8k 0.8×	1.2k 1.0×	448 0.6×	552 1.2×	207	3.9k
Luís Manso Spain	22	1.6k 0.6×	1.9k 0.8×	710 0.6×	802 1.1×	276 0.6×	153	3.3k
Tokujiro Yano Japan	35	1.8k 0.7×	1.4k 0.6×	804 0.7×	357 0.5×	423 0.9×	143	3.3k
Yoshitsugu Horio Japan	32	2.6k 1.0×	2.3k 1.0×	1.3k 1.1×	660 0.9×	276 0.6×	102	4.1k
Sun Min Lim South Korea	27	1.6k 0.6×	1.5k 0.6×	900 0.7×	521 0.7×	216 0.5×	132	2.8k
Carlo Barone Italy	31	1.4k 0.5×	2.3k 1.0×	769 0.6×	495 0.7×	671 1.4×	130	3.6k
William N. William United States	33	1.5k 0.6×	2.0k 0.9×	893 0.7×	559 0.8×	901 1.9×	109	4.0k

Countries citing papers authored by Emilio Esteban

Since Specialization

Citations

This map shows the geographic impact of Emilio Esteban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emilio Esteban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emilio Esteban more than expected).

Fields of papers citing papers by Emilio Esteban

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emilio Esteban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emilio Esteban. The network helps show where Emilio Esteban may publish in the future.

Co-authorship network of co-authors of Emilio Esteban

This figure shows the co-authorship network connecting the top 25 collaborators of Emilio Esteban. A scholar is included among the top collaborators of Emilio Esteban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emilio Esteban. Emilio Esteban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lupton, Sara J., et al.. (2025). Tissue histology and depuration of per- and polyfluoroalkyl substances (PFAS) from dairy cattle with lifetime exposures to PFAS-contaminated drinking water and feed. Food Additives & Contaminants Part A. 42(2). 223–239. 2 indexed citations

Lorca, Rebeca, Isaac Pascual, Maria C. Muñiz, et al.. (2023). Concealed Inherited Cardiomyopathies Detected in Cardio-Oncology Screening. Journal of Clinical Medicine. 13(1). 2–2. 1 indexed citations

Carmona‐Bayonas, Alberto, Raquel Hernández, David Lorente, et al.. (2023). Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer. Clinical & Translational Oncology. 25(12). 3492–3500. 5 indexed citations

Hernández, Raquel, Ana Fernández Montés, María Corral, et al.. (2023). Using the emotional functioning in clinical practice to detect psychological distress in patients with advanced thoracic and colorectal cancer. Health and Quality of Life Outcomes. 21(1). 15–15. 5 indexed citations

Gumà, Josep, Gloria Marquina, Noelia Martínez-Jáñez, et al.. (2022). Increased Quality of Life in Patients with Breakthrough Cancer Pain after Individualized Therapy: the CAVIDIOM Study. Future Oncology. 18(35). 3913–3927. 3 indexed citations

Climent, Miguel Ángel, Albert Font, Ignacio Durán, et al.. (2022). A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. European Journal of Cancer. 175. 110–119. 9 indexed citations

Lupton, Sara J., David J. Smith, E. J. Scholljegerdes, et al.. (2022). Plasma and Skin Per- and Polyfluoroalkyl Substance (PFAS) Levels in Dairy Cattle with Lifetime Exposures to PFAS-Contaminated Drinking Water and Feed. Journal of Agricultural and Food Chemistry. 70(50). 15945–15954. 26 indexed citations

Grimm, Marc‐Oliver, et al.. (2022). 1450MO Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC. Annals of Oncology. 33. S1206–S1207. 5 indexed citations

Gadgeel, Shirish M., Marina Chiara Garassino, Emilio Esteban, et al.. (2019). O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology. 14(11). S1153–S1153. 3 indexed citations

10.

Rodríguez‐Abreu, Delvys, M.C. Garassino, Emilio Esteban, et al.. (2018). KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. Annals of Oncology. 29. ix164–ix164. 4 indexed citations

11.

Garassino, Marina Chiara, Delvys Rodríguez‐Abreu, S. Gadgeel, et al.. (2018). PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189. Journal of Thoracic Oncology. 13(9). S155–S155. 1 indexed citations

12.

Lambea, J., et al.. (2016). The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. Current Oncology Reports. 18(11). 66–66. 6 indexed citations

13.

Guillém, Vicente, Miguel Ángel Climent, Javier Cassinello, et al.. (2015). Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. BMC Urology. 15(1). 1 indexed citations

14.

Pas, Tommaso De, Joo-Hang Kim, Paul Zarogoulidis, et al.. (2009). MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized. Journal of Thoracic Oncology. 4(9). 2 indexed citations

15.

Esteban, Emilio, et al.. (2008). Circulating tumor cells in breast cancer: methodology and clinical repercussions. Clinical & Translational Oncology. 10(7). 399–406. 6 indexed citations

16.

Esteban, Emilio, et al.. (2008). Screening and chemoprevention in lung cancer. Clinical & Translational Oncology. 10(5). 274–280. 1 indexed citations

17.

Vansteenkiste, Johan, A. Linder, Emilio Esteban, et al.. (2007). B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study. Journal of Thoracic Oncology. 2(8). S334–S335. 4 indexed citations

18.

Carles, Joan, Emilio Esteban, José A. Martínez-Climent, et al.. (2007). Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Annals of Oncology. 18(8). 1359–1362. 47 indexed citations

19.

Esteban, Emilio, et al.. (2007). Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. Anti-Cancer Drugs. 18(3). 291–296. 12 indexed citations

20.

Viéitez, José María, M. González‐Barón, J. R. Mel, et al.. (2002). Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer. Lung Cancer. 39(1). 77–84. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact